20 març

2019 InSiGHT Meeting

2019 InSiGHT Meeting

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) and the New Zealand Society of Gastroenterology (NZSG) are organising the 2019 InSiGHT Meeting, to be held in New Zealand for the first time from 20 to 23 March.

Dr Gabriel Capella, director of the Hereditary Cancer Program at the Catalan Institute of Oncology (ICO) is one of this year’s guest speakers. Their research focuses on studying the genetic basis of gastrointestinal cancer, with a particular interest in hereditary colorectal cancer. He took part in the Research Challenges Programme awarded to GoodGut by the Spanish Ministry of Economy and Competitiveness in 2016. After three years of study, the results will be presented at the 2019 InSiGHT Meeting on 21 March under the title RAID-LS: A non-invasive tool based on faecal bacterial signature for Lynch Syndrome surveillance.

Lynch syndrome is an inherited condition that increases risk of colon cancer, endometrial cancer and several other cancers. Doctors estimate that around 3 out of every 100 colon cancers or endometrial cancers are caused this syndrome.

Date: 20-23 March, 2019
Place: Skycity Auckland Convention Centre (New Zealand)

More information

06 març

14th Congress of the European Crohn’s and Colitis Organisation

14th Congress of the European Crohn’s and Colitis Organisation

GoodGut will participate at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO Congress), the major inflamatory bowel disease (IBD) meeting in the world attracting over 6,500 participants, will be held in Copenhagen from 6 to 9 March 2019. The ECCO Congress theme for this year is suitably titled Research drives clinical care where personalised approaches for individual patient treatments will take center stage.

A total of 1,228 abstracts have been submitted to this year’s Congress. A panel of expert reviewers have evaluated and selected the strongest and most scientifically relevant abstracts for presentation. One of them is the RAID-Monitor of GoodGut.

Joan Amoedo, researcher at GoodGut, will present the poster RAID-Monitor: a new non-invasive method to determine endoscopic activity in IBD in the section Clinical, diagnosis and outcome. RAID-Monitor is an accurate bacterial-based biomarker that correlates well with endoscopic activity in both CD and UC patients. Sensitivity and specificity obtained with our method are the highest among the techniques compared. Therefore, RAID-Monitor is a good candidate to become the non-invasive method of choice to monitor the endoscopic activity in both diseases.

Date: 6-9 March, 2019
Place: Bella Center (Copenhagen)

More information